PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME

被引：1
|
作者：
Cirillo, M. [1 ,2 ]
Carnley, B. [1 ,2 ]
Tan, P. [1 ]
Tan, D. [2 ]
Sturm, M. [2 ,3 ]
机构：
[1] Royal Perth Hosp, Haematol, Perth, WA, Australia
[2] Royal Perth Hosp, Cell & Tissue Therapies, Perth, WA, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
来源：
CYTOTHERAPY | 2018年 / 20卷 / 05期
关键词：
D O I：
10.1016/j.jcyt.2018.02.078
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
80
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
  • [42] Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
    Platzbecker, Uwe
    Fenaux, Pierre
    Steensma, David P.
    Van Eygen, Koen
    Raza, Azra
    Germing, Ulrich
    Font, Patricia
    Diez-Campelo, Maria
    Thepot, Sylvain
    Vellenga, Edo
    Patnaik, Mrinal M.
    Jang, Jun Ho
    Sherman, Laurie
    Dougherty, Souria
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Rizo, Aleksandra
    Berry, Tymara
    Feller, Faye
    Santini, Valeria
    [J]. BLOOD, 2020, 136
  • [43] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Raza, Azra
    Galili, Naomi
    Mulford, Deborah
    Smith, Scott E.
    Brown, Gail L.
    Steensma, David P.
    Lyons, Roger M.
    Boccia, Ralph
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Mesa, Ruben A.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [44] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    [J]. BLOOD, 2014, 124 (21)
  • [45] Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation
    Daher, May
    Lopez, Juliana Elisa Hidalgo
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Pemmaraju, Naveen
    Borthakur, Gautam
    Kadia, Tapan M.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine P.
    Reyes, Steven R.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2016, 128 (22)
  • [46] Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
    Raza, Azra
    Galili, Naomi
    Smith, Scott
    Godwin, John E.
    Boccia, Ralph
    Myint, Han
    Mahadevan, Daruka
    Mulford, Deborah
    Rarick, Mark
    Allison, Mary Ann
    Melnyk, Ostap
    Meng, Lisa
    Jones, Marsha
    Brown, Gail
    Young, Shelby A.
    Sekeres, Mikkael A.
    [J]. BLOOD, 2010, 116 (21) : 1198 - 1198
  • [47] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [48] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S29 - S30
  • [49] Achievement of low or intermediate-1 risk score after combination chemotherapy before stem cell transplantation (SCT) may be associated with prolonged disease-free survival (DFS) in patients with advanced myelodysplastic syndrome (MDS).
    Cermak, J
    Vitek, A
    Lukasova, M
    Michalova, K
    Cetkovsky, P
    [J]. BLOOD, 2004, 104 (11) : 404A - 404A
  • [50] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry
    Schmitz, S.
    Boettger, I
    Schnell, R.
    Lerchenmueller, C.
    Sauer, A.
    Severin, K.
    Germing, U.
    Steinmetz, H. T.
    [J]. ONKOLOGIE, 2012, 35 : 148 - 148
12345